Conservest Capital Advisors, Inc. Amgen Inc Transaction History

Conservest Capital Advisors, Inc.

  • $1.04 Billion
  • Q3 2024

A detailed history of Conservest Capital Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Conservest Capital Advisors, Inc. holds 851 shares of AMGN stock, worth $238,288. This represents 0.03% of its overall portfolio holdings.

Number of Shares
851
Previous 851 -0.0%
Holding current value
$238,288
Previous $265,000 3.4%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023
BUY
$218.65 - $271.46 $186,071 - $231,012
851 New
851 $228,000
Q4 2022

Jan 19, 2023
BUY
$229.03 - $291.01 $194,904 - $247,649
851 New
851 $0
Q1 2022

Apr 12, 2022
BUY
$219.27 - $242.57 $186,598 - $206,427
851 New
851 $206,000
Q3 2021

Oct 13, 2021
SELL
$212.27 - $248.7 $180,641 - $211,643
-851 Closed
0 $0
Q1 2021

Apr 22, 2021
BUY
$221.91 - $258.6 $188,845 - $220,068
851 New
851 $212,000
Q4 2020

Jan 13, 2021
SELL
$216.38 - $257.67 $184,139 - $219,277
-851 Closed
0 $0
Q2 2020

Jul 14, 2020
BUY
$197.81 - $242.74 $168,336 - $206,571
851 New
851 $201,000
Q1 2020

Apr 13, 2020
SELL
$182.24 - $241.7 $155,086 - $205,686
-851 Closed
0 $0
Q4 2019

Jan 27, 2020
BUY
$189.21 - $243.2 $161,017 - $206,963
851 New
851 $205,000
Q4 2018

Jan 10, 2019
SELL
$178.4 - $208.25 $326,115 - $380,681
-1,828 Closed
0 $0
Q2 2018

Jul 09, 2018
SELL
$166.05 - $186.51 $220,016 - $247,125
-1,325 Reduced 42.02%
1,828 $337,000
Q4 2017

Jan 10, 2018
BUY
$168.79 - $188.59 $2,025 - $2,263
12 Added 0.38%
3,153 $548,000
Q3 2017

Oct 12, 2017
BUY
$167.29 - $191.0 $525,457 - $599,931
3,141
3,141 $586,000

Others Institutions Holding AMGN

# of Institutions
3,123
Shares Held
409M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Conservest Capital Advisors, Inc. Portfolio

Follow Conservest Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Conservest Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conservest Capital Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email